Global Trivalent Inactivated Influenza Vaccine Supply, Demand and Key Producers, 2023-2029

Page: 100

Published Date: 04 Feb 2023

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Related Reports
Product Tags

Description

The global Trivalent Inactivated Influenza Vaccine market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

This report studies the global Trivalent Inactivated Influenza Vaccine production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for Trivalent Inactivated Influenza Vaccine, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Trivalent Inactivated Influenza Vaccine that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Trivalent Inactivated Influenza Vaccine total production and demand, 2018-2029, (K Doses)
Global Trivalent Inactivated Influenza Vaccine total production value, 2018-2029, (USD Million)
Global Trivalent Inactivated Influenza Vaccine production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Doses)
Global Trivalent Inactivated Influenza Vaccine consumption by region & country, CAGR, 2018-2029 & (K Doses)
U.S. VS China: Trivalent Inactivated Influenza Vaccine domestic production, consumption, key domestic manufacturers and share
Global Trivalent Inactivated Influenza Vaccine production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Doses)
Global Trivalent Inactivated Influenza Vaccine production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Doses)
Global Trivalent Inactivated Influenza Vaccine production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Doses)
This reports profiles key players in the global Trivalent Inactivated Influenza Vaccine market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AstraZeneca, Sanofi S.A, Abbott, GlaxoSmithKline, Merck, Novartis, Pfizer, Serum Institute of India and CSL Limited, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Trivalent Inactivated Influenza Vaccine market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Doses) and average price (US$/Dose) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Trivalent Inactivated Influenza Vaccine Market, By Region:
    United States
    China
    Europe
    Japan
    South Korea
    ASEAN
    India
    Rest of World

Global Trivalent Inactivated Influenza Vaccine Market, Segmentation by Type
    Nasal Spray
    Intramuscular Injection
    Intradermal Injection

Global Trivalent Inactivated Influenza Vaccine Market, Segmentation by Application
    Hospital
    Clinic
    Public Health Agency
    Others

Companies Profiled:
    AstraZeneca
    Sanofi S.A
    Abbott
    GlaxoSmithKline
    Merck
    Novartis
    Pfizer
    Serum Institute of India
    CSL Limited

Key Questions Answered
1. How big is the global Trivalent Inactivated Influenza Vaccine market?
2. What is the demand of the global Trivalent Inactivated Influenza Vaccine market?
3. What is the year over year growth of the global Trivalent Inactivated Influenza Vaccine market?
4. What is the production and production value of the global Trivalent Inactivated Influenza Vaccine market?
5. Who are the key producers in the global Trivalent Inactivated Influenza Vaccine market?
6. What are the growth factors driving the market demand?

Table of Contents

1 Supply Summary
    1.1 Trivalent Inactivated Influenza Vaccine Introduction
    1.2 World Trivalent Inactivated Influenza Vaccine Supply & Forecast
        1.2.1 World Trivalent Inactivated Influenza Vaccine Production Value (2018 & 2022 & 2029)
        1.2.2 World Trivalent Inactivated Influenza Vaccine Production (2018-2029)
        1.2.3 World Trivalent Inactivated Influenza Vaccine Pricing Trends (2018-2029)
    1.3 World Trivalent Inactivated Influenza Vaccine Production by Region (Based on Production Site)
        1.3.1 World Trivalent Inactivated Influenza Vaccine Production Value by Region (2018-2029)
        1.3.2 World Trivalent Inactivated Influenza Vaccine Production by Region (2018-2029)
        1.3.3 World Trivalent Inactivated Influenza Vaccine Average Price by Region (2018-2029)
        1.3.4 North America Trivalent Inactivated Influenza Vaccine Production (2018-2029)
        1.3.5 Europe Trivalent Inactivated Influenza Vaccine Production (2018-2029)
        1.3.6 China Trivalent Inactivated Influenza Vaccine Production (2018-2029)
        1.3.7 Japan Trivalent Inactivated Influenza Vaccine Production (2018-2029)
    1.4 Market Drivers, Restraints and Trends
        1.4.1 Trivalent Inactivated Influenza Vaccine Market Drivers
        1.4.2 Factors Affecting Demand
        1.4.3 Trivalent Inactivated Influenza Vaccine Major Market Trends
    1.5 Influence of COVID-19 and Russia-Ukraine War
        1.5.1 Influence of COVID-19
        1.5.2 Influence of Russia-Ukraine War

2 Demand Summary
    2.1 World Trivalent Inactivated Influenza Vaccine Demand (2018-2029)
    2.2 World Trivalent Inactivated Influenza Vaccine Consumption by Region
        2.2.1 World Trivalent Inactivated Influenza Vaccine Consumption by Region (2018-2023)
        2.2.2 World Trivalent Inactivated Influenza Vaccine Consumption Forecast by Region (2024-2029)
    2.3 United States Trivalent Inactivated Influenza Vaccine Consumption (2018-2029)
    2.4 China Trivalent Inactivated Influenza Vaccine Consumption (2018-2029)
    2.5 Europe Trivalent Inactivated Influenza Vaccine Consumption (2018-2029)
    2.6 Japan Trivalent Inactivated Influenza Vaccine Consumption (2018-2029)
    2.7 South Korea Trivalent Inactivated Influenza Vaccine Consumption (2018-2029)
    2.8 ASEAN Trivalent Inactivated Influenza Vaccine Consumption (2018-2029)
    2.9 India Trivalent Inactivated Influenza Vaccine Consumption (2018-2029)

3 World Trivalent Inactivated Influenza Vaccine Manufacturers Competitive Analysis
    3.1 World Trivalent Inactivated Influenza Vaccine Production Value by Manufacturer (2018-2023)
    3.2 World Trivalent Inactivated Influenza Vaccine Production by Manufacturer (2018-2023)
    3.3 World Trivalent Inactivated Influenza Vaccine Average Price by Manufacturer (2018-2023)
    3.4 Trivalent Inactivated Influenza Vaccine Company Evaluation Quadrant
    3.5 Industry Rank and Concentration Rate (CR)
        3.5.1 Global Trivalent Inactivated Influenza Vaccine Industry Rank of Major Manufacturers
        3.5.2 Global Concentration Ratios (CR4) for Trivalent Inactivated Influenza Vaccine in 2022
        3.5.3 Global Concentration Ratios (CR8) for Trivalent Inactivated Influenza Vaccine in 2022
    3.6 Trivalent Inactivated Influenza Vaccine Market: Overall Company Footprint Analysis
        3.6.1 Trivalent Inactivated Influenza Vaccine Market: Region Footprint
        3.6.2 Trivalent Inactivated Influenza Vaccine Market: Company Product Type Footprint
        3.6.3 Trivalent Inactivated Influenza Vaccine Market: Company Product Application Footprint
    3.7 Competitive Environment
        3.7.1 Historical Structure of the Industry
        3.7.2 Barriers of Market Entry
        3.7.3 Factors of Competition
    3.8 New Entrant and Capacity Expansion Plans
    3.9 Mergers, Acquisition, Agreements, and Collaborations

4 United States VS China VS Rest of the World
    4.1 United States VS China: Trivalent Inactivated Influenza Vaccine Production Value Comparison
        4.1.1 United States VS China: Trivalent Inactivated Influenza Vaccine Production Value Comparison (2018 & 2022 & 2029)
        4.1.2 United States VS China: Trivalent Inactivated Influenza Vaccine Production Value Market Share Comparison (2018 & 2022 & 2029)
    4.2 United States VS China: Trivalent Inactivated Influenza Vaccine Production Comparison
        4.2.1 United States VS China: Trivalent Inactivated Influenza Vaccine Production Comparison (2018 & 2022 & 2029)
        4.2.2 United States VS China: Trivalent Inactivated Influenza Vaccine Production Market Share Comparison (2018 & 2022 & 2029)
    4.3 United States VS China: Trivalent Inactivated Influenza Vaccine Consumption Comparison
        4.3.1 United States VS China: Trivalent Inactivated Influenza Vaccine Consumption Comparison (2018 & 2022 & 2029)
        4.3.2 United States VS China: Trivalent Inactivated Influenza Vaccine Consumption Market Share Comparison (2018 & 2022 & 2029)
    4.4 United States Based Trivalent Inactivated Influenza Vaccine Manufacturers and Market Share, 2018-2023
        4.4.1 United States Based Trivalent Inactivated Influenza Vaccine Manufacturers, Headquarters and Production Site (States, Country)
        4.4.2 United States Based Manufacturers Trivalent Inactivated Influenza Vaccine Production Value (2018-2023)
        4.4.3 United States Based Manufacturers Trivalent Inactivated Influenza Vaccine Production (2018-2023)
    4.5 China Based Trivalent Inactivated Influenza Vaccine Manufacturers and Market Share
        4.5.1 China Based Trivalent Inactivated Influenza Vaccine Manufacturers, Headquarters and Production Site (Province, Country)
        4.5.2 China Based Manufacturers Trivalent Inactivated Influenza Vaccine Production Value (2018-2023)
        4.5.3 China Based Manufacturers Trivalent Inactivated Influenza Vaccine Production (2018-2023)
    4.6 Rest of World Based Trivalent Inactivated Influenza Vaccine Manufacturers and Market Share, 2018-2023
        4.6.1 Rest of World Based Trivalent Inactivated Influenza Vaccine Manufacturers, Headquarters and Production Site (State, Country)
        4.6.2 Rest of World Based Manufacturers Trivalent Inactivated Influenza Vaccine Production Value (2018-2023)
        4.6.3 Rest of World Based Manufacturers Trivalent Inactivated Influenza Vaccine Production (2018-2023)

5 Market Analysis by Type
    5.1 World Trivalent Inactivated Influenza Vaccine Market Size Overview by Type: 2018 VS 2022 VS 2029
    5.2 Segment Introduction by Type
        5.2.1 Nasal Spray
        5.2.2 Intramuscular Injection
        5.2.3 Intradermal Injection
    5.3 Market Segment by Type
        5.3.1 World Trivalent Inactivated Influenza Vaccine Production by Type (2018-2029)
        5.3.2 World Trivalent Inactivated Influenza Vaccine Production Value by Type (2018-2029)
        5.3.3 World Trivalent Inactivated Influenza Vaccine Average Price by Type (2018-2029)

6 Market Analysis by Application
    6.1 World Trivalent Inactivated Influenza Vaccine Market Size Overview by Application: 2018 VS 2022 VS 2029
    6.2 Segment Introduction by Application
        6.2.1 Hospital
        6.2.2 Clinic
        6.2.3 Public Health Agency
        6.2.4 Others
    6.3 Market Segment by Application
        6.3.1 World Trivalent Inactivated Influenza Vaccine Production by Application (2018-2029)
        6.3.2 World Trivalent Inactivated Influenza Vaccine Production Value by Application (2018-2029)
        6.3.3 World Trivalent Inactivated Influenza Vaccine Average Price by Application (2018-2029)

7 Company Profiles
    7.1 AstraZeneca
        7.1.1 AstraZeneca Details
        7.1.2 AstraZeneca Major Business
        7.1.3 AstraZeneca Trivalent Inactivated Influenza Vaccine Product and Services
        7.1.4 AstraZeneca Trivalent Inactivated Influenza Vaccine Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.1.5 AstraZeneca Recent Developments/Updates
        7.1.6 AstraZeneca Competitive Strengths & Weaknesses
    7.2 Sanofi S.A
        7.2.1 Sanofi S.A Details
        7.2.2 Sanofi S.A Major Business
        7.2.3 Sanofi S.A Trivalent Inactivated Influenza Vaccine Product and Services
        7.2.4 Sanofi S.A Trivalent Inactivated Influenza Vaccine Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.2.5 Sanofi S.A Recent Developments/Updates
        7.2.6 Sanofi S.A Competitive Strengths & Weaknesses
    7.3 Abbott
        7.3.1 Abbott Details
        7.3.2 Abbott Major Business
        7.3.3 Abbott Trivalent Inactivated Influenza Vaccine Product and Services
        7.3.4 Abbott Trivalent Inactivated Influenza Vaccine Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.3.5 Abbott Recent Developments/Updates
        7.3.6 Abbott Competitive Strengths & Weaknesses
    7.4 GlaxoSmithKline
        7.4.1 GlaxoSmithKline Details
        7.4.2 GlaxoSmithKline Major Business
        7.4.3 GlaxoSmithKline Trivalent Inactivated Influenza Vaccine Product and Services
        7.4.4 GlaxoSmithKline Trivalent Inactivated Influenza Vaccine Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.4.5 GlaxoSmithKline Recent Developments/Updates
        7.4.6 GlaxoSmithKline Competitive Strengths & Weaknesses
    7.5 Merck
        7.5.1 Merck Details
        7.5.2 Merck Major Business
        7.5.3 Merck Trivalent Inactivated Influenza Vaccine Product and Services
        7.5.4 Merck Trivalent Inactivated Influenza Vaccine Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.5.5 Merck Recent Developments/Updates
        7.5.6 Merck Competitive Strengths & Weaknesses
    7.6 Novartis
        7.6.1 Novartis Details
        7.6.2 Novartis Major Business
        7.6.3 Novartis Trivalent Inactivated Influenza Vaccine Product and Services
        7.6.4 Novartis Trivalent Inactivated Influenza Vaccine Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.6.5 Novartis Recent Developments/Updates
        7.6.6 Novartis Competitive Strengths & Weaknesses
    7.7 Pfizer
        7.7.1 Pfizer Details
        7.7.2 Pfizer Major Business
        7.7.3 Pfizer Trivalent Inactivated Influenza Vaccine Product and Services
        7.7.4 Pfizer Trivalent Inactivated Influenza Vaccine Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.7.5 Pfizer Recent Developments/Updates
        7.7.6 Pfizer Competitive Strengths & Weaknesses
    7.8 Serum Institute of India
        7.8.1 Serum Institute of India Details
        7.8.2 Serum Institute of India Major Business
        7.8.3 Serum Institute of India Trivalent Inactivated Influenza Vaccine Product and Services
        7.8.4 Serum Institute of India Trivalent Inactivated Influenza Vaccine Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.8.5 Serum Institute of India Recent Developments/Updates
        7.8.6 Serum Institute of India Competitive Strengths & Weaknesses
    7.9 CSL Limited
        7.9.1 CSL Limited Details
        7.9.2 CSL Limited Major Business
        7.9.3 CSL Limited Trivalent Inactivated Influenza Vaccine Product and Services
        7.9.4 CSL Limited Trivalent Inactivated Influenza Vaccine Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.9.5 CSL Limited Recent Developments/Updates
        7.9.6 CSL Limited Competitive Strengths & Weaknesses

8 Industry Chain Analysis
    8.1 Trivalent Inactivated Influenza Vaccine Industry Chain
    8.2 Trivalent Inactivated Influenza Vaccine Upstream Analysis
        8.2.1 Trivalent Inactivated Influenza Vaccine Core Raw Materials
        8.2.2 Main Manufacturers of Trivalent Inactivated Influenza Vaccine Core Raw Materials
    8.3 Midstream Analysis
    8.4 Downstream Analysis
    8.5 Trivalent Inactivated Influenza Vaccine Production Mode
    8.6 Trivalent Inactivated Influenza Vaccine Procurement Model
    8.7 Trivalent Inactivated Influenza Vaccine Industry Sales Model and Sales Channels
        8.7.1 Trivalent Inactivated Influenza Vaccine Sales Model
        8.7.2 Trivalent Inactivated Influenza Vaccine Typical Customers

9 Research Findings and Conclusion

10 Appendix
    10.1 Methodology
    10.2 Research Process and Data Source
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. World Trivalent Inactivated Influenza Vaccine Production Value by Region (2018, 2022 and 2029) & (USD Million)
    Table 2. World Trivalent Inactivated Influenza Vaccine Production Value by Region (2018-2023) & (USD Million)
    Table 3. World Trivalent Inactivated Influenza Vaccine Production Value by Region (2024-2029) & (USD Million)
    Table 4. World Trivalent Inactivated Influenza Vaccine Production Value Market Share by Region (2018-2023)
    Table 5. World Trivalent Inactivated Influenza Vaccine Production Value Market Share by Region (2024-2029)
    Table 6. World Trivalent Inactivated Influenza Vaccine Production by Region (2018-2023) & (K Doses)
    Table 7. World Trivalent Inactivated Influenza Vaccine Production by Region (2024-2029) & (K Doses)
    Table 8. World Trivalent Inactivated Influenza Vaccine Production Market Share by Region (2018-2023)
    Table 9. World Trivalent Inactivated Influenza Vaccine Production Market Share by Region (2024-2029)
    Table 10. World Trivalent Inactivated Influenza Vaccine Average Price by Region (2018-2023) & (US$/Dose)
    Table 11. World Trivalent Inactivated Influenza Vaccine Average Price by Region (2024-2029) & (US$/Dose)
    Table 12. Trivalent Inactivated Influenza Vaccine Major Market Trends
    Table 13. World Trivalent Inactivated Influenza Vaccine Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Doses)
    Table 14. World Trivalent Inactivated Influenza Vaccine Consumption by Region (2018-2023) & (K Doses)
    Table 15. World Trivalent Inactivated Influenza Vaccine Consumption Forecast by Region (2024-2029) & (K Doses)
    Table 16. World Trivalent Inactivated Influenza Vaccine Production Value by Manufacturer (2018-2023) & (USD Million)
    Table 17. Production Value Market Share of Key Trivalent Inactivated Influenza Vaccine Producers in 2022
    Table 18. World Trivalent Inactivated Influenza Vaccine Production by Manufacturer (2018-2023) & (K Doses)
    Table 19. Production Market Share of Key Trivalent Inactivated Influenza Vaccine Producers in 2022
    Table 20. World Trivalent Inactivated Influenza Vaccine Average Price by Manufacturer (2018-2023) & (US$/Dose)
    Table 21. Global Trivalent Inactivated Influenza Vaccine Company Evaluation Quadrant
    Table 22. World Trivalent Inactivated Influenza Vaccine Industry Rank of Major Manufacturers, Based on Production Value in 2022
    Table 23. Head Office and Trivalent Inactivated Influenza Vaccine Production Site of Key Manufacturer
    Table 24. Trivalent Inactivated Influenza Vaccine Market: Company Product Type Footprint
    Table 25. Trivalent Inactivated Influenza Vaccine Market: Company Product Application Footprint
    Table 26. Trivalent Inactivated Influenza Vaccine Competitive Factors
    Table 27. Trivalent Inactivated Influenza Vaccine New Entrant and Capacity Expansion Plans
    Table 28. Trivalent Inactivated Influenza Vaccine Mergers & Acquisitions Activity
    Table 29. United States VS China Trivalent Inactivated Influenza Vaccine Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
    Table 30. United States VS China Trivalent Inactivated Influenza Vaccine Production Comparison, (2018 & 2022 & 2029) & (K Doses)
    Table 31. United States VS China Trivalent Inactivated Influenza Vaccine Consumption Comparison, (2018 & 2022 & 2029) & (K Doses)
    Table 32. United States Based Trivalent Inactivated Influenza Vaccine Manufacturers, Headquarters and Production Site (States, Country)
    Table 33. United States Based Manufacturers Trivalent Inactivated Influenza Vaccine Production Value, (2018-2023) & (USD Million)
    Table 34. United States Based Manufacturers Trivalent Inactivated Influenza Vaccine Production Value Market Share (2018-2023)
    Table 35. United States Based Manufacturers Trivalent Inactivated Influenza Vaccine Production (2018-2023) & (K Doses)
    Table 36. United States Based Manufacturers Trivalent Inactivated Influenza Vaccine Production Market Share (2018-2023)
    Table 37. China Based Trivalent Inactivated Influenza Vaccine Manufacturers, Headquarters and Production Site (Province, Country)
    Table 38. China Based Manufacturers Trivalent Inactivated Influenza Vaccine Production Value, (2018-2023) & (USD Million)
    Table 39. China Based Manufacturers Trivalent Inactivated Influenza Vaccine Production Value Market Share (2018-2023)
    Table 40. China Based Manufacturers Trivalent Inactivated Influenza Vaccine Production (2018-2023) & (K Doses)
    Table 41. China Based Manufacturers Trivalent Inactivated Influenza Vaccine Production Market Share (2018-2023)
    Table 42. Rest of World Based Trivalent Inactivated Influenza Vaccine Manufacturers, Headquarters and Production Site (States, Country)
    Table 43. Rest of World Based Manufacturers Trivalent Inactivated Influenza Vaccine Production Value, (2018-2023) & (USD Million)
    Table 44. Rest of World Based Manufacturers Trivalent Inactivated Influenza Vaccine Production Value Market Share (2018-2023)
    Table 45. Rest of World Based Manufacturers Trivalent Inactivated Influenza Vaccine Production (2018-2023) & (K Doses)
    Table 46. Rest of World Based Manufacturers Trivalent Inactivated Influenza Vaccine Production Market Share (2018-2023)
    Table 47. World Trivalent Inactivated Influenza Vaccine Production Value by Type, (USD Million), 2018 & 2022 & 2029
    Table 48. World Trivalent Inactivated Influenza Vaccine Production by Type (2018-2023) & (K Doses)
    Table 49. World Trivalent Inactivated Influenza Vaccine Production by Type (2024-2029) & (K Doses)
    Table 50. World Trivalent Inactivated Influenza Vaccine Production Value by Type (2018-2023) & (USD Million)
    Table 51. World Trivalent Inactivated Influenza Vaccine Production Value by Type (2024-2029) & (USD Million)
    Table 52. World Trivalent Inactivated Influenza Vaccine Average Price by Type (2018-2023) & (US$/Dose)
    Table 53. World Trivalent Inactivated Influenza Vaccine Average Price by Type (2024-2029) & (US$/Dose)
    Table 54. World Trivalent Inactivated Influenza Vaccine Production Value by Application, (USD Million), 2018 & 2022 & 2029
    Table 55. World Trivalent Inactivated Influenza Vaccine Production by Application (2018-2023) & (K Doses)
    Table 56. World Trivalent Inactivated Influenza Vaccine Production by Application (2024-2029) & (K Doses)
    Table 57. World Trivalent Inactivated Influenza Vaccine Production Value by Application (2018-2023) & (USD Million)
    Table 58. World Trivalent Inactivated Influenza Vaccine Production Value by Application (2024-2029) & (USD Million)
    Table 59. World Trivalent Inactivated Influenza Vaccine Average Price by Application (2018-2023) & (US$/Dose)
    Table 60. World Trivalent Inactivated Influenza Vaccine Average Price by Application (2024-2029) & (US$/Dose)
    Table 61. AstraZeneca Basic Information, Manufacturing Base and Competitors
    Table 62. AstraZeneca Major Business
    Table 63. AstraZeneca Trivalent Inactivated Influenza Vaccine Product and Services
    Table 64. AstraZeneca Trivalent Inactivated Influenza Vaccine Production (K Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 65. AstraZeneca Recent Developments/Updates
    Table 66. AstraZeneca Competitive Strengths & Weaknesses
    Table 67. Sanofi S.A Basic Information, Manufacturing Base and Competitors
    Table 68. Sanofi S.A Major Business
    Table 69. Sanofi S.A Trivalent Inactivated Influenza Vaccine Product and Services
    Table 70. Sanofi S.A Trivalent Inactivated Influenza Vaccine Production (K Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 71. Sanofi S.A Recent Developments/Updates
    Table 72. Sanofi S.A Competitive Strengths & Weaknesses
    Table 73. Abbott Basic Information, Manufacturing Base and Competitors
    Table 74. Abbott Major Business
    Table 75. Abbott Trivalent Inactivated Influenza Vaccine Product and Services
    Table 76. Abbott Trivalent Inactivated Influenza Vaccine Production (K Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 77. Abbott Recent Developments/Updates
    Table 78. Abbott Competitive Strengths & Weaknesses
    Table 79. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
    Table 80. GlaxoSmithKline Major Business
    Table 81. GlaxoSmithKline Trivalent Inactivated Influenza Vaccine Product and Services
    Table 82. GlaxoSmithKline Trivalent Inactivated Influenza Vaccine Production (K Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 83. GlaxoSmithKline Recent Developments/Updates
    Table 84. GlaxoSmithKline Competitive Strengths & Weaknesses
    Table 85. Merck Basic Information, Manufacturing Base and Competitors
    Table 86. Merck Major Business
    Table 87. Merck Trivalent Inactivated Influenza Vaccine Product and Services
    Table 88. Merck Trivalent Inactivated Influenza Vaccine Production (K Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 89. Merck Recent Developments/Updates
    Table 90. Merck Competitive Strengths & Weaknesses
    Table 91. Novartis Basic Information, Manufacturing Base and Competitors
    Table 92. Novartis Major Business
    Table 93. Novartis Trivalent Inactivated Influenza Vaccine Product and Services
    Table 94. Novartis Trivalent Inactivated Influenza Vaccine Production (K Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 95. Novartis Recent Developments/Updates
    Table 96. Novartis Competitive Strengths & Weaknesses
    Table 97. Pfizer Basic Information, Manufacturing Base and Competitors
    Table 98. Pfizer Major Business
    Table 99. Pfizer Trivalent Inactivated Influenza Vaccine Product and Services
    Table 100. Pfizer Trivalent Inactivated Influenza Vaccine Production (K Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 101. Pfizer Recent Developments/Updates
    Table 102. Pfizer Competitive Strengths & Weaknesses
    Table 103. Serum Institute of India Basic Information, Manufacturing Base and Competitors
    Table 104. Serum Institute of India Major Business
    Table 105. Serum Institute of India Trivalent Inactivated Influenza Vaccine Product and Services
    Table 106. Serum Institute of India Trivalent Inactivated Influenza Vaccine Production (K Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 107. Serum Institute of India Recent Developments/Updates
    Table 108. CSL Limited Basic Information, Manufacturing Base and Competitors
    Table 109. CSL Limited Major Business
    Table 110. CSL Limited Trivalent Inactivated Influenza Vaccine Product and Services
    Table 111. CSL Limited Trivalent Inactivated Influenza Vaccine Production (K Doses), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 112. Global Key Players of Trivalent Inactivated Influenza Vaccine Upstream (Raw Materials)
    Table 113. Trivalent Inactivated Influenza Vaccine Typical Customers
    Table 114. Trivalent Inactivated Influenza Vaccine Typical Distributors
List of Figure
    Figure 1. Trivalent Inactivated Influenza Vaccine Picture
    Figure 2. World Trivalent Inactivated Influenza Vaccine Production Value: 2018 & 2022 & 2029, (USD Million)
    Figure 3. World Trivalent Inactivated Influenza Vaccine Production Value and Forecast (2018-2029) & (USD Million)
    Figure 4. World Trivalent Inactivated Influenza Vaccine Production (2018-2029) & (K Doses)
    Figure 5. World Trivalent Inactivated Influenza Vaccine Average Price (2018-2029) & (US$/Dose)
    Figure 6. World Trivalent Inactivated Influenza Vaccine Production Value Market Share by Region (2018-2029)
    Figure 7. World Trivalent Inactivated Influenza Vaccine Production Market Share by Region (2018-2029)
    Figure 8. North America Trivalent Inactivated Influenza Vaccine Production (2018-2029) & (K Doses)
    Figure 9. Europe Trivalent Inactivated Influenza Vaccine Production (2018-2029) & (K Doses)
    Figure 10. China Trivalent Inactivated Influenza Vaccine Production (2018-2029) & (K Doses)
    Figure 11. Japan Trivalent Inactivated Influenza Vaccine Production (2018-2029) & (K Doses)
    Figure 12. Trivalent Inactivated Influenza Vaccine Market Drivers
    Figure 13. Factors Affecting Demand
    Figure 14. World Trivalent Inactivated Influenza Vaccine Consumption (2018-2029) & (K Doses)
    Figure 15. World Trivalent Inactivated Influenza Vaccine Consumption Market Share by Region (2018-2029)
    Figure 16. United States Trivalent Inactivated Influenza Vaccine Consumption (2018-2029) & (K Doses)
    Figure 17. China Trivalent Inactivated Influenza Vaccine Consumption (2018-2029) & (K Doses)
    Figure 18. Europe Trivalent Inactivated Influenza Vaccine Consumption (2018-2029) & (K Doses)
    Figure 19. Japan Trivalent Inactivated Influenza Vaccine Consumption (2018-2029) & (K Doses)
    Figure 20. South Korea Trivalent Inactivated Influenza Vaccine Consumption (2018-2029) & (K Doses)
    Figure 21. ASEAN Trivalent Inactivated Influenza Vaccine Consumption (2018-2029) & (K Doses)
    Figure 22. India Trivalent Inactivated Influenza Vaccine Consumption (2018-2029) & (K Doses)
    Figure 23. Producer Shipments of Trivalent Inactivated Influenza Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2022
    Figure 24. Global Four-firm Concentration Ratios (CR4) for Trivalent Inactivated Influenza Vaccine Markets in 2022
    Figure 25. Global Four-firm Concentration Ratios (CR8) for Trivalent Inactivated Influenza Vaccine Markets in 2022
    Figure 26. United States VS China: Trivalent Inactivated Influenza Vaccine Production Value Market Share Comparison (2018 & 2022 & 2029)
    Figure 27. United States VS China: Trivalent Inactivated Influenza Vaccine Production Market Share Comparison (2018 & 2022 & 2029)
    Figure 28. United States VS China: Trivalent Inactivated Influenza Vaccine Consumption Market Share Comparison (2018 & 2022 & 2029)
    Figure 29. United States Based Manufacturers Trivalent Inactivated Influenza Vaccine Production Market Share 2022
    Figure 30. China Based Manufacturers Trivalent Inactivated Influenza Vaccine Production Market Share 2022
    Figure 31. Rest of World Based Manufacturers Trivalent Inactivated Influenza Vaccine Production Market Share 2022
    Figure 32. World Trivalent Inactivated Influenza Vaccine Production Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 33. World Trivalent Inactivated Influenza Vaccine Production Value Market Share by Type in 2022
    Figure 34. Nasal Spray
    Figure 35. Intramuscular Injection
    Figure 36. Intradermal Injection
    Figure 37. World Trivalent Inactivated Influenza Vaccine Production Market Share by Type (2018-2029)
    Figure 38. World Trivalent Inactivated Influenza Vaccine Production Value Market Share by Type (2018-2029)
    Figure 39. World Trivalent Inactivated Influenza Vaccine Average Price by Type (2018-2029) & (US$/Dose)
    Figure 40. World Trivalent Inactivated Influenza Vaccine Production Value by Application, (USD Million), 2018 & 2022 & 2029
    Figure 41. World Trivalent Inactivated Influenza Vaccine Production Value Market Share by Application in 2022
    Figure 42. Hospital
    Figure 43. Clinic
    Figure 44. Public Health Agency
    Figure 45. Others
    Figure 46. World Trivalent Inactivated Influenza Vaccine Production Market Share by Application (2018-2029)
    Figure 47. World Trivalent Inactivated Influenza Vaccine Production Value Market Share by Application (2018-2029)
    Figure 48. World Trivalent Inactivated Influenza Vaccine Average Price by Application (2018-2029) & (US$/Dose)
    Figure 49. Trivalent Inactivated Influenza Vaccine Industry Chain
    Figure 50. Trivalent Inactivated Influenza Vaccine Procurement Model
    Figure 51. Trivalent Inactivated Influenza Vaccine Sales Model
    Figure 52. Trivalent Inactivated Influenza Vaccine Sales Channels, Direct Sales, and Distribution
    Figure 53. Methodology
    Figure 54. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Related Reports

Global Trivalent Inactivated Influenza Vaccine Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Global Trivalent Inactivated Influenza Vaccine Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

date 05 Jan 2024

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Trivalent Inactivated Influenza Vaccine market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

Global Trivalent Inactivated Influenza Vaccine Supply, Demand and Key Producers, 2024-2030

Global Trivalent Inactivated Influenza Vaccine Supply, Demand and Key Producers, 2024-2030

date 25 Feb 2024

date Pharma & Healthcare

The global Trivalent Inactivated Influenza Vaccine market size is expected to reach $ 5542.3 million by 2030, rising at a market growth of 7.3% CAGR during the forecast period (2024-2030).

Product Tags

Trivalent Inactivated Influenza Vaccine

GABA Supplements

L-carnitine Capsule

Opical Thrombin

Purchase Options

Single User License

USD4480.00

Multi User License

USD6720.00

Corporate Users License

USD8960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>